See more : OpenDoor Inc. (OPNDF) Income Statement Analysis – Financial Results
Complete financial analysis of Taysha Gene Therapies, Inc. (TSHA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Taysha Gene Therapies, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Guangdong VTR Bio-Tech Co., Ltd. (300381.SZ) Income Statement Analysis – Financial Results
- UMH Properties, Inc. (UMH) Income Statement Analysis – Financial Results
- Boundary Gold and Copper Mining Ltd. (PRZFF) Income Statement Analysis – Financial Results
- SDI Corporation (2351.TW) Income Statement Analysis – Financial Results
- bioMérieux S.A. (BMXXY) Income Statement Analysis – Financial Results
Taysha Gene Therapies, Inc. (TSHA)
About Taysha Gene Therapies, Inc.
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 15.45M | 2.50M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 2.49M | 492.00K | 9.00K | 0.00 |
| Gross Profit | 15.45M | 15.00K | -492.00K | -9.00K | 0.00 |
| Gross Profit Ratio | 100.00% | 0.60% | 0.00% | 0.00% | 0.00% |
| Research & Development | 56.78M | 91.17M | 131.94M | 31.89M | 987.00K |
| General & Administrative | 30.05M | 37.36M | 41.32M | 11.11M | 512.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | -384.00K |
| SG&A | 30.05M | 37.36M | 41.32M | 11.11M | 128.00K |
| Other Expenses | 1.07M | -18.00K | 0.00 | -17.03M | 0.00 |
| Operating Expenses | 87.89M | 128.53M | 173.27M | 43.00M | 1.12M |
| Cost & Expenses | 87.89M | 128.53M | 173.27M | 43.00M | 1.12M |
| Interest Income | 3.57M | 249.00K | 172.00K | 49.00K | 0.00 |
| Interest Expense | 5.00M | 3.80M | 1.43M | 28.00K | 0.00 |
| Depreciation & Amortization | 1.37M | 2.49M | 492.00K | 9.00K | 4.46M |
| EBITDA | -105.20M | -159.73M | -172.78M | -42.99M | 0.00 |
| EBITDA Ratio | -680.84% | -5,027.82% | 0.00% | 0.00% | 0.00% |
| Operating Income | -72.44M | -162.45M | -173.27M | -43.00M | -1.12M |
| Operating Income Ratio | -468.83% | -6,492.69% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -39.13M | -3.57M | -1.26M | -17.01M | 0.00 |
| Income Before Tax | -111.57M | -166.01M | -174.52M | -60.01M | -1.12M |
| Income Before Tax Ratio | -722.06% | -6,635.25% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 3.57M | 936.00K | -17.01M | -4.46M |
| Net Income | -111.57M | -169.58M | -175.46M | -43.00M | -1.12M |
| Net Income Ratio | -722.06% | -6,777.82% | 0.00% | 0.00% | 0.00% |
| EPS | -0.96 | -3.86 | -4.66 | -2.43 | -0.03 |
| EPS Diluted | -0.96 | -3.86 | -4.66 | -2.43 | -0.03 |
| Weighted Avg Shares Out | 116.12M | 43.95M | 37.65M | 17.67M | 36.99M |
| Weighted Avg Shares Out (Dil) | 116.12M | 43.95M | 37.65M | 17.67M | 36.99M |
Taysha Gene Therapies Announces Presentations at the Upcoming 29th Annual Meeting of the European Society of Gene & Cell Therapy (ESGCT)
DALLAS, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in...
Taysha Gene Therapies, Inc. (TSHA) CEO RA Session on Q2 2022 Results - Earnings Call Transcript
Taysha Gene Therapies, Inc. (NASDAQ:TSHA ) Q2 2022 Results Conference Call August 11, 2022 8:00 AM ET Company Participants Dr. Kimberly Lee - Chief Corporate Affairs Officer RA Session - President, Founder, and Chief Executive Officer Dr. Suyash Prasad -...
Taysha Gene Therapies Reports Second Quarter 2022 Financial Results and Provides Corporate Update
TSHA-120 treated patients in GAN demonstrated durable improvement and recoverability of sensory nerve amplitude potential (SNAP), a definitive clinical endpoint, compared to natural history
Taysha Gene Therapies to Release Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 11
DALLAS, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in...
Taysha Gene Therapies to Participate in Upcoming August Investor Conferences
BTIG Biotechnology Conference on August 8, 2022 at 12:00 pm ET
Taysha Gene Therapies to Participate in Upcoming William Blair Biotech Focus Conference 2022
President, Founder and Chief Executive Officer to participate in “AAV Gene Therapy: Delivery and Beyond” panel discussion on Wednesday, July 13, 2022 at 10:00 am ET President, Founder and Chief Executive Officer to participate in “AAV Gene Therapy: Delivery and...
Taysha Gene Therapies Announces Annual Stockholder Meeting
The Annual Stockholder Meeting on Friday, June 17, 2022 at 10 am ET The Annual Stockholder Meeting on Friday, June 17, 2022 at 10 am ET
Taysha Gene Therapies, Inc. (TSHA) CEO RA Session II on Q1 2022 Results - Earnings Call Transcript
Taysha Gene Therapies, Inc. (NASDAQ:TSHA ) Q1 2022 Earnings Conference Call May 16, 2022 8:00 AM ET Company Participants Kimberly Lee - Chief Corporate Affairs Officer RA Session II - President, Founder, and Chief Executive Officer Suyash Prasad - Chief...
Taysha Gene Therapies Reports First Quarter 2022 Financial Results and Provides Corporate Update
Initiated clinical development of TSHA-102 for Rett Syndrome under recently approved Clinical Trial Application (CTA) with preliminary Phase 1/2 data expected by year-end 2022
Taysha Gene Therapies to Release First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 16
DALLAS, May 11, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in...
Source: https://incomestatements.info
Category: Stock Reports